A director of a company in India faces criminal exposure from multiple sources simultaneously: the Companies Act 2013 (Section 447 for fraud, Sections 448-449 for false statements, and numerous other specific offence provisions); the Negotiable Instruments Act Section 141 (for dishonoured company cheques); the Prevention of Money Laundering Act (for company-related scheduled offences); regulatory agency prosecutions by SEBI, MCA, the ROC, and sector regulators; and the IPC offences of cheating, criminal breach of trust, and forgery that are routinely charged against company directors alongside the company itself when a commercial dispute turns criminal.
The legal position across all of these frameworks is, however, broadly consistent: a director is not automatically criminally liable for the company's acts. There must be a personal connection between the director and the specific act — either direct participation, specific knowledge, consent, connivance, or (in vicarious liability provisions) a specific status as the person "in charge of and responsible for the conduct of the business." An independent director who attended board meetings, asked questions, and voted in good faith on the matters before the board is in a fundamentally different position from an executive director who managed the specific business transaction that is the subject of the prosecution. The law recognises this difference. The prosecution typically ignores it. The defence must make it impossible to ignore.
GP's directors' criminal liability practice combines criminal law expertise with GP's deep corporate law background — the Companies Act knowledge that understands the legal duties and limits of each category of director, the board dynamics that determine who was actually responsible for which decisions, and the governance documentation that establishes what the accused director knew, decided, and did. This combination — rarely available in a single criminal law firm — is the difference between a generic "I didn't know" defence and a legally precise, factually grounded account of the director's specific role that the court can evaluate and accept.
From SFIO investigation response through acquittal at trial — defending directors, promoters, and company officers across every forum where personal criminal liability arises from corporate acts.
The most serious individual criminal provision in the Companies Act — Section 447 defines fraud broadly and carries imprisonment up to ten years, with a mandatory minimum of six months. Prosecuted by SFIO, MCA, SEBI, and private complainants. The defence requires establishing that the specific director did not engage in any act, omission, concealment of fact, or abuse of position with intent to deceive — a requirement that focuses the court on the director's specific role, knowledge, and intention, not the company's acts generally. GP combines the Companies Act expertise that understands the director's legal position with the criminal law expertise that identifies the specific elements the prosecution must establish for Section 447 — and the forensic accounting analysis that challenges the financial narrative underlying the fraud allegation.
The Serious Fraud Investigation Office investigates under the Companies Act — and its investigation reports form the basis for the Special Court prosecution of directors and officers. SFIO investigation management — advising directors on their rights and obligations during the investigation, managing the SFIO examination under Section 217 of the Companies Act, ensuring that the director's account of their role is presented consistently and accurately to the investigating authority, and challenging the SFIO's factual conclusions where they are based on mischaracterisations of the company's financial records or the director's specific conduct. The earlier a director engages proper legal counsel in an SFIO investigation, the better their position in the subsequent prosecution.
Independent directors are routinely named in prosecutions alongside executive directors and the company — even where their role was purely non-executive, they had no operational responsibility, and they voted in good faith on matters presented to them without knowledge of the underlying irregularities. Section 149(12) of the Companies Act provides that an independent director shall be liable only in respect of acts of omission or commission by the company which had occurred with their knowledge, attributable through board processes, and with their consent or connivance, or where they had not acted diligently. The discharge application at charge framing — demonstrating that the material on record does not establish knowledge, consent, connivance, or lack of diligence — is the primary independent director defence.
SEBI may initiate criminal prosecution of company directors and officers for SEBI Act violations — insider trading, market manipulation, disclosure failures, and RPT non-compliance. The criminal prosecution is separate from SEBI's administrative enforcement proceedings (show cause notice, adjudication order, and SAT appeal) and runs through the Special Court. Defence of SEBI criminal prosecutions requires specific capital markets law expertise alongside the criminal law framework — understanding the elements of the specific SEBI Act provision, the evidence standard required for the Special Court, and the interaction between the administrative and criminal proceedings. GP's Capital Markets practice and Criminal Defence team manage SEBI prosecutions together.
Directors named in Section 138/141 proceedings for dishonoured company cheques — including non-executive, independent, and nominee directors who had no involvement in the specific financial transaction that resulted in the dishonoured cheque. The Section 141 defence: the director was not "in charge of and responsible for the conduct of the business" in relation to the specific cheque. Board resolutions, delegation of authority matrices, the company's cheque signing authority — all establish which directors were actually responsible for the financial dealings that resulted in the dishonoured cheque, and which were not. GP identifies and presents this specific documentary evidence at the earliest opportunity — in the anticipatory bail application where possible, and in the charge framing discharge where the prosecution has already proceeded.
Directors of companies that are the subject of PMLA proceedings — where the company's business activities are alleged to be proceeds of a scheduled offence — face personal arrest, attachment of personal assets, and prosecution before the Special Court under PMLA. The personal PMLA defence requires establishing that the director's personal conduct did not constitute the act of money laundering — that the director's involvement in the company's business was not the specific act of projecting or claiming proceeds of crime as untainted property. GP manages the PMLA defence of directors alongside the AML practice — combining the criminal defence expertise with the financial investigation that challenges the ED's characterisation of the company's transactions as proceeds of crime.
Section 149(12) of the Companies Act was introduced precisely because independent directors were being named in prosecutions for acts in which they had no involvement. The provision restricts an independent director's liability to acts: (a) that occurred with their knowledge attributable through board processes; (b) with their consent or connivance; or (c) where they had not acted diligently. This creates a three-part test that every prosecution of an independent director must satisfy — and that most cannot, because the typical independent director's involvement in the specific act generating criminal liability is: (a) through board presentations that did not disclose the fraud; (b) without their knowledge; and (c) through the exercise of reasonable diligence that was deceived by management. The charge framing discharge application that identifies these three elements — and applies Section 149(12) specifically to the accusations — is the independent director's most powerful procedural remedy.
Nominee directors — appointed to the board by a private equity investor, a lender, or a strategic investor — are in a specific category that is frequently misunderstood by prosecuting agencies. A nominee director's role is to represent the appointing entity's interests at the board level — to monitor the investment and report to the investor. They are not employed by the company, not responsible for its day-to-day management, and not party to the specific financial transactions that generate criminal liability. The nominee director's defence combines Section 149(12) (for independent nominee directors) with the "in charge and responsible" test — establishing that the nominee director's role was oversight and reporting, not management and execution. GP advises nominee directors — typically investment bankers, fund managers, or professionals appointed by PE investors — from the moment any regulatory or criminal inquiry is received.
Resignation from a company's board does not end criminal liability for acts committed during the directorship. A director who resigns after the fraud has been committed but before it is discovered is still personally liable for the acts committed during their tenure. A director who was "in charge and responsible" for the business during the period of the dishonoured cheque, the fraudulent transaction, or the regulatory violation remains liable after they resign. What resignation does is fix the temporal scope of the director's liability — they are liable for the period of their directorship, not beyond. This makes the date of the offence, the date of the director's appointment, and the date of their resignation the three critical facts in every director liability case. GP establishes these dates with documentary precision from the first instruction — because the temporal defence is often the most effective one available.
The defence of a director in a Section 447 Companies Act prosecution requires three distinct bodies of expertise that are rarely united in a single firm: criminal law (the elements of the offence, the bail application, the charge framing discharge, the trial); company law (the director's specific duties and limitations under the Companies Act, the board process requirements, the meaning of "in charge and responsible"); and forensic accounting (the financial narrative that underlies the fraud allegation and that the director's conduct must be assessed against). At GP, all three are available under one instruction — the criminal advocate, the corporate lawyer, and the forensic CA work from the same instruction and the same understanding of the facts.
A director facing SFIO prosecution simultaneously faces SEBI enforcement, ED PMLA investigation, civil proceedings before the NCLT, and potential IPC charges — all requiring consistent factual positions and coordinated strategy. GP's full-service structure allows all of these proceedings to be managed from a single instruction, with a single set of facts understood by all the lawyers involved. The SEBI show cause reply does not create problems for the Special Court testimony. The SFIO statement does not contradict the NCLT affidavit. This consistency — impossible when each proceeding is managed by a different firm — is the most important protection available to a director in a multi-forum prosecution.
GP's first action in every director criminal liability case is a complete review of the board records for the period of the alleged fraud — the minutes, the audit committee reports, the management presentations, the CFO's certifications, and the correspondence between management and the board. This review is conducted by a team that understands both what the board was legally required to be told and what it was actually told — and the gap between these two is usually where the director's defence is found. The director who raised a concern that management dismissed; who voted against a resolution that passed without them; or who was presented with false information by the company's executives — has a specific, documentable defence that the board record establishes.
Complete confidentiality maintained. All client identities protected.
Defended an independent director of a listed manufacturing company charged under Section 447 of the Companies Act following an SFIO investigation into financial irregularities in the company's accounts. The SFIO had named all eight directors in the Special Court complaint. GP's discharge application at charge framing was built on three pillars: first, Section 149(12) — establishing that the director's board participation involved approving matters presented by management that concealed the fraudulent transactions; second, the audit committee record — demonstrating that the director had specifically questioned the financial provisions that the SFIO identified as fraudulent, and had been given explanations by the CFO; third, the absence of any benefit received by the independent director from the fraud. The Special Court granted the discharge application, holding that the evidence did not satisfy Section 447's intent requirement as against this director. The director avoided a trial that could have lasted years and damaged an unblemished professional reputation.
Advised a private equity fund's nominee director on a portfolio company that had issued 23 dishonoured cheques to multiple creditors, generating 23 Section 138/141 complaints in courts across four cities. The nominee director — a fund manager who had joined the board to represent the PE fund's investment — had no operational role in the portfolio company and no involvement in the financial transactions that produced the dishonoured cheques. GP filed discharge applications in all 23 matters simultaneously, presenting the nominee director's appointment letter, the board resolution confirming their non-executive status, the delegation of authority showing financial authority rested exclusively with the MD and CFO, and evidence that the nominee director had no role in the company's treasury or payment functions. All 23 courts granted the discharge applications. The nominee director avoided personal liability for a total claimed amount of Rs.14.8 crore.
Advised the CFO of a listed pharmaceutical company facing simultaneous proceedings from SEBI (insider trading prosecution in the Special Court), SFIO (Section 447 Companies Act prosecution for accounting irregularities), and the ED (PMLA investigation into the same accounting transactions). GP managed all three proceedings from a single team — ensuring that the CFO's factual account of the transactions was presented consistently to all three forums, that no document produced in one proceeding contradicted the position taken in another, and that the acquittal strategy in the SEBI criminal prosecution was developed with full awareness of the SFIO and ED proceedings' timelines and discovery requirements. The SEBI criminal prosecution — which was the most advanced of the three — was defended at trial on the basis that the CFO was not shown to have possessed unpublished price sensitive information at the time of the alleged insider trades; the SEBI Special Court acquitted the CFO after a trial spanning 14 months.
Every director criminal liability matter at GP is assessed across all active and potential proceedings simultaneously — the SFIO investigation, the SEBI inquiry, the ED investigation, the NCLT proceedings, and the criminal prosecution — with a coordinated strategy that protects the director's position in every forum. The board record review, conducted by the corporate law team alongside the criminal defence team, is completed within 48 hours of instruction.
For independent directors, nominee directors, and non-executive directors — who are most commonly wrongly named in prosecutions for acts in which they had no involvement — GP's discharge application practice before the Special Courts and Sessions Courts has achieved a consistent record of discharge before trial, protecting directors from years of criminal proceedings for acts they did not commit and could not prevent.
The three-part liability test under Section 149(12), the acts that satisfy it, the board record evidence that defeats it, and the discharge application strategy that has succeeded in multiple SFIO prosecution matters involving independent directors.
Read Guide →The definition of fraud under Section 447, the intent requirement that distinguishes fraud from negligence, the SFIO investigation process, and the charge framing discharge argument that has protected multiple directors from Section 447 prosecution.
Read Alert →Whether you are facing an SFIO investigation, SEBI prosecution, ED proceedings, Section 141 cheque complaints, or any other criminal or regulatory action as a director — call us immediately. The board record review that establishes your defence must begin before you respond to any investigative authority.
All communications are strictly confidential and legally privileged.